Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

AbbVie's acquisition of Apogee highlights that pharma will pay significantly for assets with replicable global trial data. Gaining even a one-year head start against a major drug's patent cliff (like Dupixent's) is a critical, value-creating advantage that justifies a multi-billion dollar price tag.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

GSK securing an FDA drug approval just one week after acquiring Nuvalent exemplifies the ideal pharma M&A outcome. This rapid, tangible return on investment helps explain and justify the multi-billion dollar valuations placed on biotechs with late-stage assets, as it immediately de-risks a portion of the acquisition.

Millennium's transformation into a drug development company was driven by acquisitions. Their most successful drug, Velcade, was not the main reason for acquiring its parent company. This shows that the true value drivers in M&A can be secondary, unforeseen assets.

The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.

GSK's CSO reveals their "bolt-on" deal-making focuses on late-stage clinical assets that may have failed trials or have suboptimal profiles. They acquire these assets when they believe a better trial design or repositioning can unlock the molecule's true potential, as exemplified by their acquisition of Momalotinib.

After Amgen acquired Chemocentryx, it was revealed pivotal data for its drug was misleading. This, along with other high-profile post-acquisition drug failures, highlights a pattern where sellers exit successfully, leaving the acquirer to manage the fallout and underscoring the critical need for deep diligence.